KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Change in Cash (2016 - 2025)

Pacific Biosciences Of California has reported Change in Cash over the past 16 years, most recently at $7.0 million for Q4 2025.

  • Quarterly results put Change in Cash at $7.0 million for Q4 2025, up 130.78% from a year ago — trailing twelve months through Dec 2025 was $7.7 million (up 106.13% YoY), and the annual figure for FY2025 was $7.7 million, up 106.13%.
  • Change in Cash for Q4 2025 was $7.0 million at Pacific Biosciences Of California, up from $1.7 million in the prior quarter.
  • Over the last five years, Change in Cash for PACB hit a ceiling of $850.8 million in Q1 2021 and a floor of -$473.6 million in Q2 2021.
  • Median Change in Cash over the past 5 years was -$4.1 million (2025), compared with a mean of $629368.4.
  • Biggest five-year swings in Change in Cash: tumbled 1720.29% in 2021 and later soared 3033.48% in 2023.
  • Pacific Biosciences Of California's Change in Cash stood at $35.4 million in 2021, then plummeted by 41.6% to $20.7 million in 2022, then plummeted by 1096.02% to -$205.7 million in 2023, then soared by 89.01% to -$22.6 million in 2024, then skyrocketed by 130.78% to $7.0 million in 2025.
  • The last three reported values for Change in Cash were $7.0 million (Q4 2025), $1.7 million (Q3 2025), and -$4.1 million (Q2 2025) per Business Quant data.